4427 studies found for:    "Leukemia"
Show Display Options
RSS Create an RSS feed from your search for:
"Leukemia"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Unknown  Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia
Conditions: Leukemias;   Acute Myeloid Leukemia (AML);   Acute Lymphocytic Leukemia (ALL);   Adult T Cell Leukemia (ATL);   Chronic Myeloid Leukemia (CML-BP);   Chronic Lymphocytic Leukemia (CLL);   Myelodysplastic Syndrome (MDS);   Chronic Myelomonocytic Leukemia (CMML)
Intervention: Drug: Terameprocol (EM-1421)
2 Recruiting Dose Escalation Study of EPZ-5676 in Pediatric Patients With Leukemias Bearing a Rearrangement of the MLL Gene
Conditions: Leukemia;   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Acute Leukemias
Intervention: Drug: EPZ-5676
3 Completed Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias
Conditions: Acute Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Chronic Myelogenous Leukemia;   High-risk Myelodysplastic Syndrome;   Chronic Lymphocytic Leukemia;   Advanced Myelofibrosis
Intervention: Drug: TH-302
4 Active, not recruiting Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia.
Conditions: Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Chronic Lymphocytic Leukemia
Intervention: Drug: lenalidomide
5 Active, not recruiting PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Leukemia;   Leukemia, Lymphocytyc;   CLL (Chronic Lymphocytic Leukemia);   SLL (Small Lymphocytic Lymphoma)
Intervention: Drug: PCI 32765
6 Recruiting Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients
Conditions: Leukemia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Leukemia
Interventions: Drug: Lirilumab;   Drug: Rituximab
7 Terminated A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)
Conditions: Leukemia, Lymphoblastic, Acute, T-cell;   Myelogenous Leukemia;   Chronic Lymphocytic Leukemia;   Myelodysplastic Syndromes
Intervention: Drug: MK0752, (Notch Inhibitor)
8 Active, not recruiting Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)
Conditions: Acute Myelocytic Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelocytic Leukemia;   Chronic Lymphocytic Leukemia;   Myelodysplastic Syndromes
Intervention: Drug: ON 01910.Na
9 Recruiting Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
Conditions: Hairy Cell Leukemia (HCL);   Chronic Lymphocytic Leukemia (CLL);   Non-Hodgkins Lymphoma (NHL);   Cutaneous T Cell Lymphoma (CTCL);   Adult T Cell Lymphoma (ATL)
Intervention:
10 Active, not recruiting Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)
Conditions: B-cell Chronic Lymphocytic Leukemia;   Hematopoietic/Lymphoid Cancer;   Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia
Interventions: Drug: carfilzomib;   Other: Cytokine Assessment;   Other: Pharmacodynamic Studies;   Other: Proteosome Inhibition Assessment;   Other: Pharmacogenomic Studies
11 Active, not recruiting Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia
Conditions: B-Cell Prolymphocytic Leukemia;   Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   T-Cell Prolymphocytic Leukemia
Interventions: Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Procedure: Hematopoietic Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Radiation: Total-Body Irradiation
12 Recruiting Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma;   T-Cell Large Granular Lymphocyte Leukemia
Interventions: Drug: Fludarabine Phosphate;   Biological: Rituximab;   Radiation: Total-Body Irradiation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
13 Terminated A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL)
Conditions: Leukemia;   Leukemia, Lymphocytic, Chronic
Intervention: Drug: Motexafin gadolinium
14 Recruiting Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Conditions: B-Cell Prolymphocytic Leukemia;   Plasma Cell Leukemia;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Childhood Hodgkin Lymphoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Non-Hodgkin Lymphoma;   Refractory Plasma Cell Myeloma;   Refractory Small Lymphocytic Lymphoma;   T-Cell Prolymphocytic Leukemia;   Waldenstrom Macroglobulinemia
Interventions: Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Fludarabine Phosphate;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Drug: Melphalan;   Procedure: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Procedure: Allogeneic Bone Marrow Transplantation;   Other: Laboratory Biomarker Analysis;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
15 Completed Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML)
Conditions: Leukemia, Lymphocytic, Acute;   Leukemia;   Leukemia Acute Promyelocytic Leukemia (APL);   Leukemia Acute Lymphoid Leukemia (ALL);   Leukemia Chronic Myelogenous Leukemia (CML);   Leukemia Acute Myeloid Leukemia (AML);   Leukemia Chronic Lymphocytic Leukemia (CLL)
Intervention: Procedure: Allogeneic hematopoietic cell transplantation
16 Completed Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Leukemia;   Lymphoma
Intervention: Drug: motexafin gadolinium
17 Completed Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia
Conditions: Anemia;   Leukemia, Lymphocytic, Chronic;   Leukemia, Lymphocytic;   Cancer;   Neoplasms;   Quality of Life
Intervention: Drug: epoetin alfa
18 Completed MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Acute Leukemias of Ambiguous Lineage;   Acute Myeloid Leukemia/Transient Myeloproliferative Disorder;   Acute Undifferentiated Leukemia;   Aggressive NK-cell Leukemia;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blastic Phase Chronic Myelogenous Leukemia;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Intraocular Lymphoma;   Juvenile Myelomonocytic Leukemia;   Mast Cell Leukemia;   Myeloid/NK-cell Acute Leukemia;   Noncutaneous Extranodal Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Primary Central Nervous System Hodgkin Lymphoma;   Primary Central Nervous System Non-Hodgkin Lymphoma;   Progressive Hairy Cell Leukemia, Initial Treatment;   Prolymphocytic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Unspecified Childhood Solid Tumor, Protocol Specific;   Waldenström Macroglobulinemia
Interventions: Drug: Akt inhibitor MK2206;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study
19 Active, not recruiting 8-Chloro-Adenosine in Chronic Lymphocytic Leukemia
Conditions: Leukemia;   Chronic Lymphocytic Leukemia
Intervention: Drug: 8-Chloro-Adenosine
20 Terminated
Has Results
5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia
Conditions: Chronic Lymphocytic Leukemia;   Leukemia
Intervention: Drug: 5-Azacytidine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years